Core Insights - Acrivon Therapeutics, Inc. (ACRV) is anticipated to report earnings soon, with favorable conditions suggesting a potential earnings beat [1] - Recent earnings estimate revisions indicate positive trends for ACRV, as analysts have raised their estimates ahead of the earnings report [1] - The Most Accurate Estimate for ACRV's current quarter is a loss of 79 cents per share, which is an improvement compared to the Zacks Consensus Estimate of a loss of 89 cents per share [1] Earnings ESP Analysis - Acrivon Therapeutics has a Zacks Earnings ESP of +11.63%, indicating a positive outlook heading into the earnings season [1] - A positive Zacks Earnings ESP has historically led to positive surprises and outperformance in the market, with a nearly 70% success rate in producing positive surprises [2] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have shown an average annual return of over 28% [2]

Core Insights - Acrivon Therapeutics presents initial positive clinical data from the Phase 2 ACR-368 trial, showing a 50% confirmed overall response rate in OncoSignature-positive patients with ovarian and endometrial cancers [1][3] - The AP3 patient selection platform has demonstrated its ability to predict responders to ACR-368 treatment, with a statistically significant p-value of 0.0038 [1][3] - ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, has an accelerated IND filing timeline now expected in Q3 2024 [1][4] Clinical Data Highlights - Initial clinical data from the ongoing Phase 2b trial includes 26 patients, with 10 OncoSignature-positive and 16 OncoSignature-negative [1][3] - A confirmed overall response rate of 50% was observed in OncoSignature-positive patients, while no responders were found in the OncoSignature-negative group [3][4] - The median duration of response has not yet been reached, and all confirmed responders continue treatment [3] AP3 Platform Validation - The ACR-368 OncoSignature assay has shown prospective validation in identifying patients likely to respond to ACR-368 monotherapy [2][3] - The assay effectively segregated RECIST responders, confirming a 50% overall response rate in OncoSignature-positive patients compared to 0% in OncoSignature-negative patients [3] ACR-2316 Development - ACR-2316 is designed for superior single-agent activity and is advancing rapidly, with IND filing now expected in Q3 2024 and clinical trial initiation anticipated in Q4 2024 [1][4] - The compound aims to address significant unmet treatment needs across a broad range of tumors [2][4] Event and Presentation - Acrivon hosted a corporate R&D event to present these findings, with a live and recorded webcast available for investors [5]

Core Insights - Warren Buffett's Berkshire Hathaway has increased its stake in Liberty Media Corp, acquiring over 1.3 million shares at prices ranging from $25.36 to $26.55, totaling more than $29.3 million, bringing its total holdings to approximately 69 million shares [4][6] - Insider buying activity has generally slowed, but notable purchases were made in various sectors, including media, biotechnology, and industrials [1][19] Liberty Media - Berkshire Hathaway has boosted its stake in Liberty Media Corp (NASDAQ: LSXMK) to around 69 million shares after a previous purchase of over $66 million [4] - The stock price of Liberty Media has decreased by about 15% since the beginning of the year, and the company is in the process of merging with Sirius XM Holdings Inc [4][6] Acrivon Therapeutics - Perceptive Advisors purchased over 2.3 million shares of Acrivon Therapeutics Inc (NASDAQ: ACRV) at $8.50 per share, totaling around $20 million [9] - The stock has risen over 114% since the start of the year, largely due to a $130 million funding announcement, with a mean price target suggesting an additional upside of approximately 84% [9] UL Solutions - Insiders, including CEO Jennifer Scanlon, bought more than 590,600 shares of UL Solutions Inc (NYSE: ULS) at $28.00 per share, costing over $16.5 million [12] - The shares were last seen trading around $34, indicating a positive post-IPO performance despite recent market fluctuations [12] OncoCyte - Broadway Partners and other insiders acquired nearly 2.5 million shares of OncoCyte Corp (NASDAQ: OCX) at prices between $2.91 and $2.95, totaling over $7.1 million [14] - The stock has declined almost 25% in the past 90 days, but remains above its 52-week low of $2.08, with a consensus price target of $3.90 [14] GrafTech International - Colonial House Capital purchased around 2.3 million shares of GrafTech International Ltd (NYSE: EAF) at $1.78 per share, costing about $4.1 million [17] - The stock has fallen more than 32% year-to-date, with a consensus price target of $1.75, indicating limited analyst support for buying shares [17] Other Notable Insider Buying - Recent insider purchases were reported at companies including AES, America's Car-Mart, Federal Agricultural Mortgage, Lovesac, Neogen, Rocket Companies, RXO, SAIC, Walgreens Boots Alliance, and WD-40 [19]

Core Insights - Acrivon Therapeutics is hosting a virtual corporate R&D event on April 24, 2024, to present updates on its precision oncology pipeline and engage in an interactive Q&A session [1][2] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), which identifies patients whose tumors are likely to respond to specific treatments [3] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms, facilitating drug design optimization and the creation of proprietary OncoSignature companion diagnostics [3] Pipeline Developments - The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer based on OncoSignature-predicted sensitivity [3] - The ACR-368 OncoSignature test, which is not yet approved, has been evaluated in preclinical studies, including two blinded, prospectively-designed studies involving tumor biopsies from previous trials [3] - The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay to identify ovarian cancer patients who may benefit from ACR-368 treatment [3] - Acrivon is also developing ACR-2316, a potent WEE1/PKMYT1 inhibitor, and other preclinical programs leveraging the AP3 platform [3]

Group 1 - Acrivon Therapeutics announced a $130 million private placement to fund its product pipeline development [1] - The company sold 8,235,000 shares at $8.50 per share and pre-funded warrants for 7,060,000 shares at $8.49 each [1] - The funding will support the development of ACR-368, ACR-2316, and an undisclosed cell cycle regulatory program [2] Group 2 - ACRV stock surged by 54.9% with over 14 million shares traded, significantly above its average daily volume of about 73,000 shares [2] - The investment comes from notable healthcare and life sciences investors, including RA Capital Management and Perceptive Advisors [1]

WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase a ...

Core Viewpoint - There is a strong argument for investing in small cap stocks currently, but a recommendation to exit the Russell 2000 and related ETFs due to underperformance and seasonal factors is emphasized [2][8]. Group 1: Small Cap Stocks vs. Large Cap Stocks - Anticipated easing by the Federal Reserve may benefit small cap stocks more than large caps [2]. - Small caps have historically underperformed large caps over the past five years, suggesting a potential for mean reversion [2]. - The recent tech rally has disproportionately favored large cap indices like the S&P 500, indicating a possible slowdown [2]. Group 2: Performance Metrics - From 2016 to 2023, the Russell 2000 underperformed the S&P 500 by 28.4% during the months of May to August [2]. - Year-to-date returns show the Russell 2000 at 10.16%, while the S&P 500 has higher returns [3]. - Over the past year, the Russell 2000 has returned 27.88%, compared to 15.93% for the S&P 600 [3]. Group 3: Comparison of Small Cap Indices - The Russell 2000 has the largest company market cap at $46 billion, while the S&P 600's largest is $7 billion [5]. - The Russell 2000 has no restrictions on IPOs, leading to a more volatile composition compared to the S&P 600 and CRSP [5]. - The S&P 600 requires positive earnings for inclusion, which may lead to stronger balance sheets compared to the Russell 2000 [5][9]. Group 4: Recommended ETFs and Funds - IWM, which tracks the Russell 2000, is recommended for exit, while IJR (S&P 600) and VB (CRSP) are suggested alternatives [6][8]. - AVUV, an actively managed small cap value ETF, has shown superior returns compared to the Russell 2000 Value Index [6][7]. - DFSV, another actively managed ETF, has also performed well but is recommended to be less favorable than AVUV [7]. Group 5: Conclusion - Investors should consider switching from Russell 2000 tracking investments to alternatives like IJR, VB, or AVUV based on their investment preferences and market outlook [8].

Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-41551 Acrivon Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) | D ...

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed for superior single-agent efficacy [1][2] - The company utilizes its proprietary AP3 platform to identify patient responders and mechanisms of drug resistance, enhancing the potential for effective cancer treatments [6] Group 1: Product Development - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at addressing limitations of existing WEE1 and PKMYT1 inhibitors [2] - Acrivon is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for specific cancer types [6] Group 2: Research Presentation - Acrivon will present data at the AACR Annual Meeting from April 5-10, 2024, showcasing the potential of ACR-2316 and insights from the AP3 platform regarding resistance mechanisms to ACR-368 [1][3] - The presentations will include a poster on ACR-2316's design and efficacy, as well as findings on overcoming resistance to ACR-368 through combination treatments [3][4]